| Bioactivity | Cyclic(YCDGFYACYMDV) is a HER2 signaling pathway inhibitor with anti-cancer activity. This compound self-assembles into nanoparticles in aqueous solution and transforms into nanofibers upon specific binding to HER2 on cancer cells. This transformation disrupts HER2 dimerization and subsequent downstream signaling events, leading to cancer cell apoptosis (Apoptosis). The inhibitory effects on HER2 positive breast cancer have been demonstrated to be effective in a murine xenograft model[1]. |
| CAS | 535959-77-4 |
| Sequence | Tyr-Cys-Asp-Gly-Phe-Tyr-Ala-Cys-Tyr-Met-Asp-Val (Disulfide bridge: Cys2-Cys8) |
| Shortening | YCDGFYACYMDV (Disulfide bridge: Cys2-Cys8) |
| Formula | C65H82N12O20S3 |
| Molar Mass | 1447.61 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Zhang L, et al. Transformable peptide nanoparticles arrest HER2 signalling and cause cancer cell death in vivo. Nat Nanotechnol. 2020 Feb;15(2):145-153. |
Cyclic(YCDGFYACYMDV)
CAS: 535959-77-4 F: C65H82N12O20S3 W: 1447.61
Cyclic(YCDGFYACYMDV) is a HER2 signaling pathway inhibitor with anti-cancer activity. This compound self-assembles into
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.